Takeda has said it intends to move quickly ahead with regulatory filings for oveporexton, its orexin agonist for sleep disorder narcolepsy, after a clean sweep of positive efficacy data in two phase 3 ...
After 10 weeks of training at IMG Academy in Florida, 13 athletes from the International Player Pathway program will take the field for a workout in front of NFL scouts. IPP consultant Scott Pioli ...
GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor TIM-3, after its cobolimab candidate flunked a phase 3 trial in lung cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback